KR20180089151A - Composition for improving skin barrier function and skin moisturizing agent comprising an extract of Caesalpinia sappn L. - Google Patents
Composition for improving skin barrier function and skin moisturizing agent comprising an extract of Caesalpinia sappn L. Download PDFInfo
- Publication number
- KR20180089151A KR20180089151A KR1020170013879A KR20170013879A KR20180089151A KR 20180089151 A KR20180089151 A KR 20180089151A KR 1020170013879 A KR1020170013879 A KR 1020170013879A KR 20170013879 A KR20170013879 A KR 20170013879A KR 20180089151 A KR20180089151 A KR 20180089151A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- skin
- extraction method
- barrier function
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 230000008591 skin barrier function Effects 0.000 title claims abstract description 28
- 230000003020 moisturizing effect Effects 0.000 title abstract description 20
- 235000007627 Caesalpinia Nutrition 0.000 title 1
- 241000522234 Caesalpinia Species 0.000 title 1
- 239000002537 cosmetic Substances 0.000 claims abstract description 36
- 239000004480 active ingredient Substances 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 14
- 210000001578 tight junction Anatomy 0.000 claims abstract description 13
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 10
- 230000036541 health Effects 0.000 claims abstract description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 38
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 22
- 239000002904 solvent Substances 0.000 claims description 13
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 12
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 11
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 11
- 238000002137 ultrasound extraction Methods 0.000 claims description 11
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 10
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 9
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 230000004888 barrier function Effects 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 5
- 239000006072 paste Substances 0.000 claims description 4
- 239000000344 soap Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000004909 Moisturizer Substances 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims 4
- 229940069521 aloe extract Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 21
- 102000000591 Tight Junction Proteins Human genes 0.000 abstract description 12
- 108010002321 Tight Junction Proteins Proteins 0.000 abstract description 12
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 241000209639 Biancaea sappan Species 0.000 abstract 3
- 210000003491 skin Anatomy 0.000 description 29
- 230000014509 gene expression Effects 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- -1 tracant Substances 0.000 description 11
- UWHUTZOCTZJUKC-JKSUJKDBSA-N brazilin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C=C1OC2 UWHUTZOCTZJUKC-JKSUJKDBSA-N 0.000 description 10
- UWHUTZOCTZJUKC-CVEARBPZSA-N brazilin Natural products C12=CC(O)=C(O)C=C2C[C@@]2(O)[C@@H]1C1=CC=C(O)C=C1OC2 UWHUTZOCTZJUKC-CVEARBPZSA-N 0.000 description 10
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 8
- 102000002029 Claudin Human genes 0.000 description 8
- 108050009302 Claudin Proteins 0.000 description 8
- 229940072056 alginate Drugs 0.000 description 8
- 229920000615 alginic acid Polymers 0.000 description 8
- 235000010443 alginic acid Nutrition 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 102000004161 Claudin-4 Human genes 0.000 description 7
- 108090000601 Claudin-4 Proteins 0.000 description 7
- 102000018157 Claudin-9 Human genes 0.000 description 6
- 108050007295 Claudin-9 Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 102000002038 Claudin-18 Human genes 0.000 description 5
- 108050009324 Claudin-18 Proteins 0.000 description 5
- 102000004056 Claudin-2 Human genes 0.000 description 5
- 108090000580 Claudin-2 Proteins 0.000 description 5
- 102000004106 Claudin-3 Human genes 0.000 description 5
- 108090000599 Claudin-3 Proteins 0.000 description 5
- 102000003859 Claudin-6 Human genes 0.000 description 5
- 108090000229 Claudin-6 Proteins 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 108090000304 Occludin Proteins 0.000 description 5
- 102000003940 Occludin Human genes 0.000 description 5
- 102100034686 Tight junction protein ZO-1 Human genes 0.000 description 5
- 108700007340 Zonula Occludens-1 Proteins 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 102000003899 claudin 8 Human genes 0.000 description 5
- 108090000239 claudin 8 Proteins 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 102000004162 Claudin-1 Human genes 0.000 description 4
- 108090000600 Claudin-1 Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 101000785523 Homo sapiens Tight junction protein ZO-2 Proteins 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 102100026637 Tight junction protein ZO-2 Human genes 0.000 description 4
- 229940037003 alum Drugs 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- LINOMUASTDIRTM-QGRHZQQGSA-N deoxynivalenol Chemical compound C([C@@]12[C@@]3(C[C@@H](O)[C@H]1O[C@@H]1C=C(C([C@@H](O)[C@@]13CO)=O)C)C)O2 LINOMUASTDIRTM-QGRHZQQGSA-N 0.000 description 4
- 229930002954 deoxynivalenol Natural products 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- LINOMUASTDIRTM-UHFFFAOYSA-N vomitoxin hydrate Natural products OCC12C(O)C(=O)C(C)=CC1OC1C(O)CC2(C)C11CO1 LINOMUASTDIRTM-UHFFFAOYSA-N 0.000 description 4
- 235000015162 Caesalpinia sappan Nutrition 0.000 description 3
- 244000306301 Caesalpinia sappan Species 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 102000004057 Claudin-5 Human genes 0.000 description 3
- 108090000582 Claudin-5 Proteins 0.000 description 3
- 102000018156 Claudin-7 Human genes 0.000 description 3
- 108050007296 Claudin-7 Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000049280 MARVEL Domain Containing 2 Human genes 0.000 description 3
- 108050009393 MARVEL domain-containing protein 2 Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 235000021283 resveratrol Nutrition 0.000 description 3
- 229940016667 resveratrol Drugs 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000221095 Simmondsia Species 0.000 description 2
- 235000004433 Simmondsia californica Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000037427 ion transport Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JKMPXGJJRMOELF-UHFFFAOYSA-N 1,3-thiazole-2,4,5-tricarboxylic acid Chemical compound OC(=O)C1=NC(C(O)=O)=C(C(O)=O)S1 JKMPXGJJRMOELF-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- 102100039164 Acetyl-CoA carboxylase 1 Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102100033473 Cingulin Human genes 0.000 description 1
- 101710122611 Cingulin Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 101000963424 Homo sapiens Acetyl-CoA carboxylase 1 Proteins 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010040082 Junctional Adhesion Molecule A Proteins 0.000 description 1
- 102100022304 Junctional adhesion molecule A Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- MLWIYODOURBGPI-MRXNPFEDSA-N brazilein Chemical compound C12=CC=C(O)C=C2OC[C@@]2(O)C1=C1C=C(O)C(=O)C=C1C2 MLWIYODOURBGPI-MRXNPFEDSA-N 0.000 description 1
- MLWIYODOURBGPI-UHFFFAOYSA-N brazilein Natural products C12=CC=C(O)C=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 MLWIYODOURBGPI-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 150000002215 flavonoids Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- JVGNTXGHBHMJDO-QHHAFSJGSA-N sappanchalcone Chemical compound COC1=CC(O)=CC=C1C(=O)\C=C\C1=CC=C(O)C(O)=C1 JVGNTXGHBHMJDO-QHHAFSJGSA-N 0.000 description 1
- JVGNTXGHBHMJDO-UHFFFAOYSA-N sappanchalcone Natural products COC1=CC(O)=CC=C1C(=O)C=CC1=CC=C(O)C(O)=C1 JVGNTXGHBHMJDO-UHFFFAOYSA-N 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002024 transepithelial electric resistance (teer) Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
Description
본 발명은 소목 추출물을 유효성분으로 함유하는 피부 장벽기능 강화용 화장료 조성물 및 피부보습제에 관한 것으로, 보다 구체적으로, 소목 추출물을 유효성분으로 함유하여 피부 장벽기능 강화, 피부 보습에 효과가 있는 화장료 조성물 및 피부보습제, 건강기능식품 및 타이트정션 형성 촉진 조성물에 관한 것이다.The present invention relates to a cosmetic composition for enhancing skin barrier function and a skin moisturizing agent containing an alginate extract as an active ingredient and more particularly to a cosmetic composition containing an alginate extract as an active ingredient, A skin moisturizing agent, a health functional food and a composition for promoting tight junction formation.
피부보습은 피부의 수분과 탄력을 유지할 뿐 아니라, 해로운 외부 환경 요인을 방어하는 관점에서 필수적인 요소이다. 이러한 피부 보습 효과는 각질층(stratum corneum)의 자연보습인자(NMF, natural moisturizing factor)와 히알루론산의 수분 결합 능력으로 인해 조절 되는데, 이러한 보습 능력은 피부장벽 기능과도 밀접한 관련이 있다. 피부장벽 기능은 노화 및 외부 여러 요소들에 의해 파괴될 수 있으며, 이러한 피부장벽 손상은 결국 피부 수분량 감소와 주름 발생의 원인이 될 수 있다. 이러한 피부 보습 및 피부 장벽과 직접적 관련이 있는 것이 바로 밀착연접, 즉, 타이트정션(tight junction, TJ)이다. TJ은 두 개 이상의 세포 간 부착을 연계하고, 세포외기질을 통해 물질수송을 조절하는 다중 단백질 복합체(multiprotein complexes)로 Occludin, Claudin 등이 알려진다. TJ 관련 단백질들은 세포막 사이에 transmembrane domain을 가지고 있어 세포막 내에 강하게 박혀 있으나 Zona occludens-1(ZO-1), ZO-2, Cingulin 등과 actin cytoskeleton과 결합하고 다양한 신호 전달 단백질과의 상호작용 등을 하며, 이를 통해 세포 간의 부착(adhesion), 수분 및 이온 등의 물질 이동을 조절하는 물리적 장벽기능(barrier function)을 가진다. 이러한 피부세포의 장벽기능은 피부 표면의 약산성(pH 5.5) 유지와 각질층 내 항균 펩타이드 등에 직접 관여하며 바이러스나 박테리아와 같은 외부 침입을 막고 각질세포 분열과 분화를 조절하는 등 정상적 피부 보호 및 유지에 중요한 역할을 수행한다고 할 수 있다. 그러나 최근 많은 연구들에 따르면 TJ은 수분 유지, 이온 수송 조절 등에 의한 피부 보습 기능뿐 아니라 암세포의 유전자 전사와 종양 전이의 억제, 세포증식 조절 등에도 밀접한 관련이 있는 것으로 알려지고 있다. 이러한 TJ의 기능은 조직의 구획을 정하고 항상성을 유지하기 위해 상당히 중요하다. 특히 TJ 관련 단백질 중 Claudin family 단백질에 의한 구조적 변화 발생은 암세포의 초기 침윤과 전이에 관련되어 있어 TJ 구조의 변화 및 소실이 관찰된다. 따라서 TJ 관련 단백질 (Claudins, Occludin, ZO-1, ZO-2 등) 및 TJ 관련 단백질 (E-cadherin 등) mRNA 발현에 관여하는 조절 메커니즘 연구의 중요성이 커지고 있다. 그 예로 Claudin 1과 Claudin 7은 전이성 유방암 세포에서 그 발현이 억제되지만 다른 암 조직에서 Claudin 3과 Claudin 4 발현량은 현저히 증가된다고 알려진다. 또한 자궁경부암의 경우에는 비종양 조직에 비해 Claudin 5와 Claudin 9의 발현량이 저해되지만 Claudin 8 발현은 오히려 크게 증가된다. Claudin 8은 인간 골육종 세포인 U2OS의 악성 증식에 관여하고 신장암 진단을 위한 바이오마커로도 사용된다. Na+ 흡수 메커니즘에서는 Claudin 8 과발현 조절이 중요하다. 이러한 연구들로 볼 때 TJ 관련 단백질의 발현조절은 암 발생 초기 단계의 결과라기보다 구조적 변화 등에 의해 암이 발생되고 진행 및 전이에 원인이 되는 것으로 이해되어진다. 이 뿐 아니라 TJ 관련 단백질 중 Claudin 단백질들은 세포이동(cell migration)에도 직접적으로 관여한다는 연구결과가 있어 이와 관련된 연구가 활발히 진행되고 있다. Skin moisturization is essential not only to maintain skin's moisture and elasticity, but also to defend harmful external environmental factors. This moisturizing effect is controlled by the natural moisturizing factor (NMF) of the stratum corneum and the ability of the hyaluronic acid to bind to moisture, which is closely related to the skin barrier function. Skin barrier function can be destroyed by aging and various external factors, and such skin barrier damage can eventually cause skin moisture loss and wrinkles. The tight junction, TJ, is directly related to skin moisturization and skin barrier. TJ is a multiprotein complex (Occludin, Claudin, etc.) that associates two or more intercellular adhesion and regulates mass transport through extracellular matrix. TJ-related proteins have a transmembrane domain between the cell membranes and are strongly embedded in the cell membrane, but they bind to actin cytoskeleton with Zona occludens-1 (ZO-1), ZO-2, and Cingulin and interact with various signal transduction proteins. It has a barrier function to regulate cell adhesion, moisture and ion transport. The barrier function of these skin cells is directly related to the maintenance of the weak acidity (pH 5.5) of the skin surface and the antimicrobial peptide in the stratum corneum. It is important for normal skin protection and maintenance such as prevention of external invasion such as viruses and bacteria and control of keratinocyte division and differentiation It can be said that it plays a role. However, according to recent studies, it has been known that TJ is closely related to skin moisturizing function such as water retention and ion transport regulation, as well as to inhibit gene transcription, tumor metastasis and cell proliferation of cancer cells. The function of these TJs is crucial in order to determine the compartment of the tissue and to maintain homeostasis. Especially, structural changes of the TJ - related proteins by Claudin family proteins are related to the early invasion and metastasis of cancer cells, so that the TJ structure changes and disappears. Therefore, it is becoming increasingly important to study the regulation mechanisms involved in the expression of TJ-related proteins (Claudins, Occludin, ZO-1, ZO-2, etc.) and TJ-related proteins (E-cadherin, etc.). For example, the expression of Claudin 1 and Claudin 7 is inhibited in metastatic breast cancer cells, but the amount of expression of Claudin 3 and Claudin 4 in other cancer tissues is remarkably increased. In the case of cervical cancer, expression of Claudin 5 and Claudin 9 is inhibited, but the expression of Claudin 8 is rather increased. Claudin 8 is involved in malignant proliferation of human osteosarcoma cell U2OS and is also used as a biomarker for the diagnosis of kidney cancer. Claudin 8 overexpression regulation is important in the Na + uptake mechanism. These studies suggest that regulation of TJ-related protein expression may be caused by structural changes rather than by early stages of cancer development, leading to cancer and its progression and metastasis. In addition, studies have shown that Claudin proteins among TJ-related proteins are directly involved in cell migration.
한편, 소목나무(蘇木, Caesalpinia sappan L.)는 콩과(Leguminosae)에 속하는 식물로 소방목(蘇方木), 소방(蘇方), 적목(赤木), 홍자(紅紫) 등으로 불리고, 우리나라에는 자생하고 있지 않으며, 중국의 푸젠성(福建省), 광동성(廣東省), 광시성(廣西省), 구이저우성(貴州省), 위난성(雲南省), 하이남(海南) 섬, 타이완 등에 분포하고 있다. 소목나무의 줄기와 굵은 가지의 속부분(心材)을 소목(蘇木)이라고 하며, 심장과 혈관에 대한 작용, 중추 억제 작용, 항균 작용이 있다고 알려져있다 (김창민 외,중약대사전, pp.3130, 1998).On the other hand, the common tree (蘇木, Caesalpinia sappan L.) is a plant belonging to the leguminosae. It is called a fire wood (蘇 方 木), fire (蘇 方), red wood (紅 木) It is not native to China and it is located in Fujian Province, Guangdong Province, Guangxi Province, Guizhou Province, Yunnan Province, Hainan Island, Taiwan and others. It is known that the trunk of stemwood and coarse branches of callus tree are called 木 木, and it has been known that it acts on heart and blood vessels, has central inhibitory action, and has antimicrobial action (Kim Chang Min et al., Chinese Medicine Dictionary, pp.3130, 1998).
소목에 대한 연구로는 위암 세포주에 대한 세포 독성 효과 (Park, K. J., et al., Kor. J. Pharmacogn. 28(4), pp233-238,1997), 항산화 효과 (Lim, D. K., et al., Kor. J. Food Sci. Technol. 28(1), pp77 , 1996 ; Badami Shrishailappa, Moorkoth Sudheer et al., Bio. Pharm. Bull., 26(11), pp1534-1537, 2003) 및 항염 효과와 항균 소취 효과(Kim, Y. S.et al., Kor. J. Pharmacogn. 26(3), pp265-272, 1995 ; Hikino H Tet al., Planta Med., 31(3), pp214-220, 1977 ; Kim, K. J. et al., J. ethnopharmacology , 91(1), pp81-87, 2004 ; Xu, H. X. and Lee, S. F, phytotheraphy Research, 18(8), pp647-651, 2004), 항경련효과 (Baek, N. I. et al., Arch. Pharm. Res. 23(4), pp344-348, 2004), 항보체 활성 (Oh, S. R. et al., Planta Med., 64(5), pp456-458, 1998) 및 토포이소머라제(topoisomerase) I 억제 활성 등 (Jeon, W.The antioxidative effect (Lim, DK, et al., 2002) was also investigated in a study on the toxicity of carboxymethylcellulose to gastric cancer cell line (Park, KJ, et al., Kor. J. Pharmacogn. 28 (4), pp233-238,1997) , 26 (11), pp1534-1537, 2003), and anti-inflammatory effects and anti-inflammatory effects, Antibacterial deodorizing effect (Kim, YSet al., Kor J. Pharmacogn. 26 (3), pp 265-272, 1995, Hikino H et al., Planta Med., 31 (3), pp 214-220, 1977 , JS et al., J. Ethnopharmacology, 91 (1), pp 81-87, 2004; Xu, HX and Lee, S. F, phytotheraphy Research, 18 (8), pp 647-651, 2004) (Baek, NI et al., Arch Pharm Res. 23 (4), pp344-348, 2004), anti-complement activity (Oh, SR et al., Planta Med., 64 (5), pp 456-458, 1998 ) And topoisomerase I inhibitory activity (Jeon, W. et al.
K. et al., Kor. J. Pharmacogn. 30(1), pp1-6, 1999)에 관한 보고가 있으나, 아직까지 피부 장벽기능 강화 활성에 대하여 개시된 바는 없다.K. et al., Kor. J. Pharmacogn. 30 (1), pp. 1-6, 1999). However, there has not yet been disclosed a skin barrier function enhancing activity.
소목의 주요성분으로는 헤마톡실린(hematoxylin)과 플라보노이드(flavonoid) 구조를 갖는 무색의 원색소인 브라질린(brazilin)이 알려져 있으며, 브라질린은 공기 중에 산화되어 브라질레인(brazilein) (Moon, C. K. et al., Arch. Pharm.Res. 11(2), pp149-154, 1988)이 된다. 소목의 주성분인 브라질린은 고혈압 (Moon, C. K., et al., Drug Chem. Toxicol.15(1), pp81, 1992), 혈소판에서의 칼슘 농도 조절 (Hwang, G. S. et al., Arch. Pharm. Res. 21(6), pp774-778, 1998) 및 혈액에서의 혈당 저하 작용 (Kim, S. G., et al., Arch. Pharm. Res. 21(2), pp140-146, 1998)등이 보고되었다. 또한, 소목의 성분 중 하나인 사판칼콘(sappanchalcone)은 혈소판 응고를 억제한다는 보고가 있다 (Morota, T. et al., Jpn. Kokai Tokkyo Koho, pp6, 1990). 그러나, 소목의 상기 성분들의 피부 장벽기능 강화 활성에 대하여 개시된 바는 없다.The major components of the cabbage are hematoxylin and brazilin, a colorless source pigment having a flavonoid structure. Brazilians are oxidized in the air and become brazilein (Moon, CK et al., Arch. Pharm. Res. 11 (2), pp. 149-154, 1988). Brassilin, which is the main component of guinea pigs, has been implicated in hypertension (Moon, CK, et al., Drug Chem. Toxicol.15 (1), pp81, 1992), calcium concentration regulation in platelets (Hwang, GS et al., Arch Pharm. (Kim, SG, et al., Arch Pharm Res. 21 (2), pp140-146, 1998), etc. have been reported . In addition, it has been reported that sappanchalcone, one of the components of the alum, suppresses platelet clotting (Morota, T. et al., Jpn. Kokai Tokkyo Koho, pp6, 1990). However, there is no disclosure about the skin barrier function enhancing activity of the above components of the joining.
이에 본 발명에서는 다양한 천연물 소재 중 소목추출물(Caesalpinia sappan L.)이 피부 장벽기능 강화에 우수한 효능이 있음을 발견하고 본 발명을 완성하였다.Accordingly, the present invention has found that Caesalpinia sappan L. has an excellent effect on skin barrier function enhancement among various natural materials, and completed the present invention.
따라서 본 발명의 목적은 소목 추출물을 유효성분으로 함유하는 피부 장벽기능 강화용 화장료 조성물, 피부 장벽기능 개선용 건강기능식품, 타이트정션 형성 촉진 조성물 및 피부보습제를 제공하는 것이다.Accordingly, an object of the present invention is to provide a cosmetic composition for enhancing skin barrier function, a health functional food for improving skin barrier function, a composition for promoting tight junction formation, and a skin moisturizing agent, which comprise a root extract as an active ingredient.
본 발명의 또 다른 목적은 소목 추출물을 유효성분으로 함유하는 피부 장벽기능 강화용 화장료 조성물을 인간의 피부에 도포하여 피부 장벽 기능을 강화시키는 효과를 갖는 것을 특징으로 하는 화장 방법을 제공하는 것이다.It is still another object of the present invention to provide a make-up method characterized by having an effect of applying a cosmetic composition for enhancing a skin barrier function containing an alginate extract as an active ingredient to human skin to enhance skin barrier function.
상술한 바와 같은 목적을 달성하기 위한, 본 발명에 따른 피부 장벽기능 강화용 화장료 조성물은 소목 추출물을 유효성분으로 함유한다.In order to achieve the above-mentioned object, the cosmetic composition for skin barrier function enhancement according to the present invention contains an alginate extract as an active ingredient.
본 발명에 따른 화장료 조성물에 있어서, 상기 소목 추출물은 (a) 물, 탄소수 1-4의 무수 또는 함수 저급 알코올, 아세톤, 에틸 아세테이트, 클로로포름, 부틸아세테이트 및 1,3-부틸렌 글리콜로 구성된 군으로부터 선택되는 추출용매를 이용한 용매 추출법, (b) 초임계 추출법 또는 (c) 초음파 추출법을 이용하여 추출한 것을 특징으로 한다.In the cosmetic composition according to the present invention, the cosmetic composition of the present invention comprises (a) water, an anhydrous or a lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, butyl acetate and 1,3- (B) a supercritical extraction method, or (c) an ultrasonic extraction method.
상기 화장료 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이로 구성된 군으로부터 선택되는 제형일 수 있다.The cosmetic composition may be in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray .
본 발명에 따른 피부 장벽기능 개선용 건강기능식품은 소목 추출물을 유효성분으로 함유한다.The health functional food for skin barrier function improvement according to the present invention contains a root extract as an active ingredient.
본 발명에 따른 건강기능식품에 있어서, 상기 소목 추출물은 (a) 물, 탄소수 1-4의 무수 또는 함수 저급 알코올, 아세톤, 에틸 아세테이트, 클로로포름, 부틸아세테이트 및 1,3-부틸렌 글리콜로 구성된 군으로부터 선택되는 추출용매를 이용한 용매 추출법, (b) 초임계 추출법 또는 (c) 초음파 추출법을 이용하여 추출한 것을 특징으로 한다.In the health functional food according to the present invention, the extract of the present invention comprises (a) water, an anhydrous or a lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, butyl acetate and 1,3-butylene glycol , (B) supercritical extraction, or (c) ultrasonic extraction.
본 발명에 따른 타이트정션 형성 촉진 조성물은 소목 추출물을 유효성분으로 함유한다.The composition for promoting tight junction formation according to the present invention contains a root extract as an active ingredient.
본 발명에 따른 타이트정션 형성 촉진 조성물에 있어서, 상기 소목 추출물은 (a) 물, 탄소수 1-4의 무수 또는 함수 저급 알코올, 아세톤, 에틸 아세테이트, 클로로포름, 부틸아세테이트 및 1,3-부틸렌 글리콜로 구성된 군으로부터 선택되는 추출용매를 이용한 용매 추출법, (b) 초임계 추출법 또는 (c) 초음파 추출법을 이용하여 추출한 것을 특징으로 한다.In the composition for accelerating tight junction formation according to the present invention, the joining extract may comprise (a) water, an anhydrous or a lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, butyl acetate and 1,3-butylene glycol (B) a supercritical extraction method, or (c) an ultrasonic extraction method.
본 발명에 따른 피부 보습제는 소목 추출물을 유효성분으로 함유한다.The skin moisturizing agent according to the present invention contains an alginate extract as an active ingredient.
본 발명에 따른 피부 보습제에 있어서, 상기 소목 추출물은 (a) 물, 탄소수 1-4의 무수 또는 함수 저급 알코올, 아세톤, 에틸 아세테이트, 클로로포름, 부틸아세테이트 및 1,3-부틸렌 글리콜로 구성된 군으로부터 선택되는 추출용매를 이용한 용매 추출법, (b) 초임계 추출법 또는 (c) 초음파 추출법을 이용하여 추출한 것을 특징으로 한다.In the skin moisturizing agent according to the present invention, the extract of the present invention comprises (a) water, an anhydrous or a lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, butyl acetate and 1,3-butylene glycol (B) a supercritical extraction method, or (c) an ultrasonic extraction method.
본 발명에 따른 화장방법은 소목 추출물을 유효성분으로 함유하는 피부 장벽기능 강화용 화장료 조성물을 인간의 피부에 도포하여 피부 장벽 기능을 강화시키는 효과를 갖는 것을 특징으로 한다.The cosmetic method according to the present invention is characterized in that the cosmetic composition for enhancing skin barrier function containing an alginate extract as an active ingredient is applied to human skin to enhance the skin barrier function.
본 발명의 소목 추출물을 유효성분으로 함유하는 피부 장벽기능 강화용 화장료 조성물, 건강기능식품 및 타이트정션 형성 촉진 조성물 및 피부보습제에 따르면, 피부 장벽기능을 강화하고 피부 보습에 우수한 효과가 있다.According to the cosmetic composition for enhancing skin barrier function, the composition for promoting health functional food, the composition for promoting tight junction formation, and the skin moisturizer containing the extract of the present invention as an active ingredient, the skin barrier function is strengthened and the skin moisturizing effect is excellent.
도 1은 소목 추출물에 의한 피부 각질 형성세포의 타이트정션 관련 유전자인 Claudin mRNA 발현량을 측정한 결과이다.
도 2는 트랜스 상피 전기 저항(TEER) 실험을 통한 세포 장벽 강화 효과 측정 결과이다.FIG. 1 shows the results of measuring the amount of expression of Claudin mRNA, which is a gene related to tight junction of dermal keratinocytes by the extract of jojoba.
FIG. 2 shows the measurement results of the cell barrier strengthening effect through the trans-epithelial electrical resistance (TEER) experiment.
본 발명은 다양한 변환을 가할 수 있고 여러 가지 실시 예를 가질 수 있는바, 특정 실시 예들을 도면에 예시하고 상세한 설명에서 상세하게 설명하고자 한다. 그러나, 이는 본 발명을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변환, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다. 본 발명을 설명함에 있어서 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다.BRIEF DESCRIPTION OF THE DRAWINGS The present invention is capable of various modifications and various embodiments, and specific embodiments are illustrated in the drawings and will be described in detail in the detailed description. It is to be understood, however, that the invention is not to be limited to the specific embodiments, but includes all modifications, equivalents, and alternatives falling within the spirit and scope of the invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the present invention will be described in detail with reference to the accompanying drawings.
본 출원에서 사용한 용어는 단지 특정한 실시예를 설명하기 위해 사용된 것으로, 본 발명을 한정하려는 의도가 아니다. 단수의 표현은 문맥상 명백하게 다르게 뜻하지 않는 한, 복수의 표현을 포함한다. 본 출원에서, "포함하다" 또는 "가지다" 등의 용어는 명세서상에 기재된 특징, 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것이 존재함을 지정하려는 것이지, 하나 또는 그 이상의 다른 특징들이나 숫자, 단계, 동작, 구성요소, 부품 또는 이들을 조합한 것들의 존재 또는 부가 가능성을 미리 배제하지 않는 것으로 이해되어야 한다.The terminology used in this application is used only to describe a specific embodiment and is not intended to limit the invention. The singular expressions include plural expressions unless the context clearly dictates otherwise. In the present application, the terms "comprises" or "having" and the like are used to specify that there is a feature, a number, a step, an operation, an element, a component or a combination thereof described in the specification, But do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, or combinations thereof.
제1, 제2 등의 용어는 다양한 구성요소들을 설명하는데 사용될 수 있지만, 상기 구성요소들은 상기 용어들에 의해 한정되어서는 안 된다. 상기 용어들은 하나의 구성요소를 다른 구성요소로부터 구별하는 목적으로만 사용된다.The terms first, second, etc. may be used to describe various components, but the components should not be limited by the terms. The terms are used only for the purpose of distinguishing one component from another.
이하, 첨부된 도면을 참조하여 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to the accompanying drawings.
본 발명에 따른 피부 장벽기능 강화용 화장료 조성물은 소목 추출물을 유효성분으로 함유한다.The cosmetic composition for enhancing skin barrier function according to the present invention contains an alginate extract as an active ingredient.
본 발명의 소목 추출물은 당업계에 공지된 통상의 방법에 따라, 즉, 통상적인 온도와 압력의 조건 하에서, 통상적인 용매를 사용하여 제조될 수 있다. 본 발명의 소목 추출물은 정제수, 메탄올, 에탄올, 글리세린, 에틸아세테이트, 부틸렌글리콜, 프로필렌글리콜, 디클로로메탄, 클로로포름, 에틸에테르, 부틸렌글라이콜 및 헥산으로 구성된 군으로부터 선택된 1종 이상의 추출용매를 사용하여 추출되며, 바람직하게는 에탄올, 70% 에탄올 또는 물을 사용하여 추출되며, 보다 바람직하게는 70% 에탄올을 사용하여 추출되는 것을 특징으로 한다.The guinea extract of the present invention can be prepared using conventional solvents known in the art, that is, under the conditions of ordinary temperature and pressure, using conventional solvents. The extract of the present invention can be obtained by using at least one extraction solvent selected from the group consisting of purified water, methanol, ethanol, glycerin, ethyl acetate, butylene glycol, propylene glycol, dichloromethane, chloroform, ethyl ether, butyleneglycol, And is preferably extracted with ethanol, 70% ethanol or water, more preferably with 70% ethanol.
한편, 본 발명의 소목 추출물은 상기한 추출 용매뿐만 아니라, 다른 추출 용매를 이용하여도 실질적으로 동일한 효과를 나타내는 추출물이 얻어질 수 있다는 것은 당업자에게 자명한 것이다.On the other hand, it is obvious to those skilled in the art that the extract of the present invention can be obtained not only by the above-mentioned extraction solvent but also by using other extraction solvent.
또한, 본 발명의 추출물은 상술한 추출 용매에 의한 추출물 뿐만 아니라, 통상적인 정제 과정을 거친 추출물도 포함한다. 예컨대, 이산화탄소에 의한 감압, 고온에 의한 초임계추출법에 의한 추출, 초음파를 이용한 추출법에 의한 추출, 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 이용한 분리, 다양한 크로마토그래피 (크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 활성 분획도 본 발명의 추출물에 포함되는 것이다.In addition, the extract of the present invention includes not only the extract obtained by the above-mentioned extraction solvent, but also an extract obtained through a conventional purification process. For example, decompression by carbon dioxide, extraction by supercritical extraction with high temperature, extraction by extraction using ultrasound, separation by ultrafiltration membrane with constant molecular weight cutoff value, various chromatography (size, charge, hydrophobic or affinity The active fraction obtained through various purification methods which have been further carried out, such as separation by means of separation according to sex), is also included in the extract of the present invention.
또한, 본 발명은 상기 추출물이 상온에서 냉침, 가열 여과하여 얻어진 액상물, 추가로 용매를 감압농축 또는 동결건조하여 얻은 것임을 특징으로 하는 피부외용제 조성물을 제공한다.Further, the present invention provides a composition for external application for skin, wherein the extract is obtained by subjecting the extract to a liquid substance obtained by cold filtration and heat filtration at room temperature, and furthermore, the solvent is concentrated under reduced pressure or lyophilized.
또한, 본 발명의 소목 추출물은 화장료 조성물 전체에 대해서 0.001-30.0중량% 함유되며, 바람직하게는 0.1-10.0 중량% 함유되는 것을 특징으로 한다. 상기 추출물의 함량이 0.001중량% 미만인 경우에는 피부개선 효과가 나타나지 않으며, 30.0중량% 이상인 경우에는 함유량 증가에 대한 효과 증대 정도가 미미하며, 제형상의 안전 및 안정성에 문제가 있으며 경제적이지도 못하다.The extract of the present invention is contained in an amount of 0.001-30.0% by weight, preferably 0.1-10.0% by weight, based on the total amount of the cosmetic composition. When the content of the extract is less than 0.001% by weight, the effect of improving the skin is not exhibited. When the content of the extract is more than 30.0% by weight, the effect of increasing the content of the extract is insignificant and there is a problem in safety and stability.
본 발명에 따르면, 소목 추출물은 피부 각질형성 세포의 피부장벽 기능 강화 효과 및 보습효과가 뛰어나다.According to the present invention, the extract of Alaska Extract has excellent skin barrier function and moisturizing effect on skin keratinocytes.
따라서, 이러한 소목 추출물을 유효성분으로 포함하는 본 발명의 화장료 조성물은 뛰어난 보습 효과를 갖는다.Therefore, the cosmetic composition of the present invention comprising such a root extract as an active ingredient has excellent moisturizing effect.
본 발명의 화장료 조성물에 포함되는 성분은 유효 성분으로서 상기 유효성분 이외에 화장품 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.The ingredients contained in the cosmetic composition of the present invention include, in addition to the above-mentioned effective ingredients, the ingredients conventionally used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, vitamins, And a carrier.
본 발명의 화장료 조성물은 당 업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used in the form of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as the carrier component .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로 플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Cellulose, aluminum metahydroxide, bentonite, agar or tracant, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component is selected from aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.
또한, 본 발명은 본 발명의 소목 추출물을 함유하는 화장료 조성물을 인간의 피부에 도포하는 것을 특징으로 하는 화장방법을 제공한다.The present invention also provides a makeup method characterized by applying a cosmetic composition containing a root extract of the present invention to human skin.
본 발명의 화장 방법은 본 발명의 화장료 조성물을 인간의 피부에 도포하는 모든 화장 방법을 일컫는다. 즉, 화장료 조성물을 피부에 도포하는 당업계에 공지된 모든 방법이 본 발명의 화장 방법에 속한다.The cosmetic process of the present invention refers to all the cosmetic processes for applying the cosmetic composition of the present invention to human skin. That is, all methods known in the art for applying the cosmetic composition to the skin belong to the cosmetic method of the present invention.
본 발명의 화장료 조성물은 단독 또는 중복 도포하여 사용하거나, 본 발명 이외의 다른 화장료 조성물과 중복 도포하여 사용할 수 있다. 또한 본 발명에 따른 피부 보호 효과가 우수한 화장료 조성물은 통상적인 사용방법에 따라 사용될 수 있으며, 사용자의 피부 상태 또는 취향에 따라 그 사용횟수를 달리할 수 있다.The cosmetic composition of the present invention may be used alone or in combination, or may be used by overlapping with other cosmetic compositions other than the present invention. In addition, the cosmetic composition having excellent skin protection effect according to the present invention can be used according to a conventional method of use, and the number of times of use can be varied depending on the skin condition or taste of the user.
본 발명의 화장료 조성물이 비누, 계면활성제 함유 클렌징 또는 계면활성제 비함유 클렌징 제형일 경우, 피부에 도포한 후 닦아내거나 떼거나 물로 씻어낼 수도 있다. 구체적인 예로서, 상기 비누는 액상비누, 가루비누, 고형비누 및 오일비누이며, 상기 계면활성제 함유 클린징 제형은 클렌징폼, 클렌징 워터, 클렌징 수건 및 클렌징 팩이며, 상기 계면활성제 비함유 클렌징 제형은 클렌징크림, 클렌징 로션, 클렌징 워터 및 클렌징 겔이며, 이에 한정되는 것은 아니다.When the cosmetic composition of the present invention is a soap, a surfactant-containing cleansing agent, or a surfactant-free cleansing agent, it may be applied to the skin and then wiped off or removed or washed with water. The surfactant-containing cleansing formulation is a cleansing foam, a cleansing water, a cleansing towel, and a cleansing pack. The surfactant-free cleansing formulation may be a cleansing cream, , Cleansing lotion, cleansing water and cleansing gel, but is not limited thereto.
본 발명의 소목 추출물을 포함하는 화장료 조성물을 인간의 피부에 도포하는 화장방법을 수행하면, 피부 각질형성세포의 피부 장벽기능 회복 효과 및 피부보습 효과를 얻을 수 있다.By carrying out the cosmetic method of applying the cosmetic composition containing the extract of the present invention to human skin, the skin barrier function recovery effect and the skin moisturizing effect of the keratinocyte can be obtained.
본 발명의 일실시예로서, 본 발명에 따른 피부 장벽기능 개선용 건강기능식품은 소목 추출물을 유효성분으로 함유한다.In one embodiment of the present invention, the health functional food for skin barrier function improvement according to the present invention contains a root extract as an active ingredient.
본 발명에 따른 건강기능식품에 있어서, 상기 소목 추출물은 (a) 물, 탄소수 1-4의 무수 또는 함수 저급 알코올, 아세톤, 에틸 아세테이트, 클로로포름, 부틸아세테이트 및 1,3-부틸렌 글리콜로 구성된 군으로부터 선택되는 추출용매를 이용한 용매 추출법, (b) 초임계 추출법 또는 (c) 초음파 추출법을 이용하여 추출한 것을 특징으로 한다.In the health functional food according to the present invention, the extract of the present invention comprises (a) water, an anhydrous or a lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, butyl acetate and 1,3-butylene glycol , (B) supercritical extraction, or (c) ultrasonic extraction.
본 발명에 따른 타이트정션 형성 촉진 조성물은 소목 추출물을 유효성분으로 함유한다.The composition for promoting tight junction formation according to the present invention contains a root extract as an active ingredient.
본 발명에 따른 타이트정션 형성 촉진 조성물에 있어서, 상기 소목 추출물은 (a) 물, 탄소수 1-4의 무수 또는 함수 저급 알코올, 아세톤, 에틸 아세테이트, 클로로포름, 부틸아세테이트 및 1,3-부틸렌 글리콜로 구성된 군으로부터 선택되는 추출용매를 이용한 용매 추출법, (b) 초임계 추출법 또는 (c) 초음파 추출법을 이용하여 추출한 것을 특징으로 한다.In the composition for accelerating tight junction formation according to the present invention, the joining extract may comprise (a) water, an anhydrous or a lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, butyl acetate and 1,3-butylene glycol (B) a supercritical extraction method, or (c) an ultrasonic extraction method.
본 발명에 따른 피부 보습제는 소목 추출물을 유효성분으로 함유한다.The skin moisturizing agent according to the present invention contains an alginate extract as an active ingredient.
본 발명에 따른 피부 보습제에 있어서, 상기 소목 추출물은 (a) 물, 탄소수 1-4의 무수 또는 함수 저급 알코올, 아세톤, 에틸 아세테이트, 클로로포름, 부틸아세테이트 및 1,3-부틸렌 글리콜로 구성된 군으로부터 선택되는 추출용매를 이용한 용매 추출법, (b) 초임계 추출법 또는 (c) 초음파 추출법을 이용하여 추출한 것을 특징으로 한다.In the skin moisturizing agent according to the present invention, the extract of the present invention comprises (a) water, an anhydrous or a lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, butyl acetate and 1,3-butylene glycol (B) a supercritical extraction method, or (c) an ultrasonic extraction method.
이하에서는 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 다만, 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다 할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It should be understood, however, that these examples are for illustrative purposes only and are not to be construed as limiting the scope of the present invention.
실시예Example 1: 소목 추출물의 제조 1: Preparation of extract
소목(Caesalpinia sappan L.)은 경동시장에서 구입하고, 강제 공기 순환 방식으로 시료를 건조하였다. 이렇게 건조된 샘플을 분쇄하고, 100℃에서 2시간 동안 열수로 추출하였다. 상기 생성된 추출물을 감압하에서 로터리 증발기(Eyela)에서 농축하고, 감압하에서 동결 건조하여 소목 추출물을 수득하였다.The cauliflower (Caesalpinia sappan L.) was purchased at Kyungdong market and dried by forced air circulation method. The dried sample was pulverized and extracted with hot water at 100 DEG C for 2 hours. The resulting extract was concentrated under reduced pressure in a rotary evaporator (Eyela) and lyophilized under reduced pressure to obtain a guinea pig extract.
실시예Example 2: RNA 추출 및 quantitative real-time 2: RNA extraction and quantitative real-time PCRPCR
6 well culture dish에 HaCaT 세포를 2 × 105 cells/well로 분주하고 24시간 동안 배양하였다. 그 후 각각의 well에 소목 및 브라질린을 세포 생존율에 영향을 미치지 않는 1 ㎍/㎖로 처리하여 다시 48시간 동안 배양하였다. HaCaT cells were plated at 2 × 10 5 cells / well in a 6-well culture dish and cultured for 24 hours. Subsequently, each of the wells and the brassin was treated with 1 ㎍ / ㎖, which did not affect the cell viability, and cultured again for 48 hours.
각 시료가 첨가된 배지를 제거한 후 RiboEx (GeneAll, Korea) 1 ml로 세포를 lysis 한 다음, Hybrid-R RNA purification kit (GeneAll, Korea)를 이용하여 RNA를 추출하고 The Qubit 2.0 Fluorometer (Invitrogen, USA)로 정량하였다. 이렇게 추출하여 정량한 total RNA로 cDNA를 합성하기 위하여 Total RNA 2 ㎍, dNTP mix (10 mM) 2 ㎕, Random Hexamer (100 pmol/㎕) 2 ㎕를 넣은 후 DEPC-treated water로 총 부피 20 ㎕가 되도록 조정하였다. 65에서 5분간 반응시킨 후 즉시 얼음에 냉각시킨 다음, 각각 5X M-MLV RT reaction buffer (Promega, USA) 8 ㎕, M-MLV reverse transcriptase (Promega, USA) 2 ㎕, RNase inhibitor (Enzynomics, Korea) 2 ㎕, DEPC-treated water 8 ㎕를 추가적으로 첨가해 주었다. After removing the medium containing each sample, the cells were lysed with 1 ml of RiboEx (GeneAll, Korea), RNA was extracted using Hybrid-R RNA purification kit (GeneAll, Korea) and the Qubit 2.0 fluorometer (Invitrogen, USA ). 2 μl of total RNA, 2 μl of dNTP mix (10 mM) and 2 μl of Random Hexamer (100 pmol / μl) were added to the total RNA extracted and quantified, and then 20 μl of total volume was added with DEPC-treated water Respectively. (RNase inhibitor, Enzynomics, Korea) was added to each well of a 5 × M-MLV RT reaction buffer (Promega, USA), 2 μl of M-MLV reverse transcriptase (Promega, USA) 2 μl, and 8 μl of DEPC-treated water were further added.
그 뒤 실온에서 10분간 둔 후에 50에서 1시간 동안 반응시켜 cDNA를 합성하였다. 추후 실험에는 이렇게 합성한 cDNA를 1/5로 희석시켜 사용하였다. 소목 추출물 및 브라질린 처리에 의해 TJ 관련 유전자인 Claudin family의 mRNA 발현량을 비교해 보기 위하여 quantitative real-time PCR (qRT-PCR)을 실시하였다. 2X Prime Q-mater Mix (GENET BIO, Korea) 10 ㎕, 10 pmol/㎕ forward primer와 10 pmol/㎕ reverse primer를 각각 1.5 ㎕, nuclease free water 2 ㎕, 합성한 후 1/5로 희석시킨 cDNA 5 ㎕를 넣은 뒤 95에서 3분 후 95에서 denaturation 20초, 58에서 annealing 20초, 72에서 elongation 20초를 40 cycle 실시하는 조건 하에서 AriaMx (Agilent, USA)를 이용하여 qRT-PCR을 수행하였다. After incubation at room temperature for 10 minutes, cDNA was synthesized by reacting at 50 for 1 hour. For further experiments, the synthesized cDNA was diluted 1/5. Quantitative real-time PCR (qRT-PCR) was performed to compare mRNA expression levels of the Claudin family, a TJ-related gene, by the treatment with the extract of guinea-pig and brazilin. 10 μl of 2X Prime Q-mater Mix (GENET BIO, Korea), 1.5 μl of 10 pmol / μl forward primer and 10 pmol / μl reverse primer, 2 μl of nuclease free water, And then qRT-PCR was performed using AriaMx (Agilent, USA) under conditions of 95 minutes at 95, denaturation at 20 seconds at 58, annealing at 58 for 20 seconds, and elongation for 20 seconds at 72 for 40 cycles.
실험군과 대조군의 internal standard로 β-actin을 사용하였고, 실험에 사용한 primer의 염기서열은 하기 표 1과 같다. Β-actin was used as an internal standard for the experimental and control groups, and the nucleotide sequences of the primers used in the experiments are shown in Table 1 below.
본 실시예에서는 피부를 구성하는 각질 형성 세포의 생물학적 메커니즘에 미치는 영향을 알아보기 위해 대표적인 TJ 관련 유전자인 Claudin mRNA 발현량을 측정하였다. MTS 실험 결과 세포 생존율에 영향을 주지 않는 것으로 확인된 1 ㎍/㎖ 농도 조건하에서 소목 및 브라질린을 48시간 동안 처리한 후 internal standard로 β-actin을 이용하여 대조군 대비 스테비올 처리군의 Claudin 1, 2, 3, 4, 5, 6, 7, 8, 9, 18, Occludin, JAM A, ZO-1, ZO-2, Tricellulin의 mRNA 발현량을 비교해 보았다. In this example, the expression of Claudin mRNA, a typical TJ-related gene, was measured in order to examine the effect on the biological mechanism of keratinocytes constituting the skin. The results of the MTS test were as follows: 1. ㎍ / ㎖ concentration of bovine and brazilin was treated for 48 h, and β - actin was used as an internal standard for
도 1은 소목 추출물에 의한 피부 각질 형성세포의 타이트정션 관련 유전자인 Claudin mRNA 발현량을 측정한 결과이다. 도 1을 참조하면, Claudin 5는 발현량이 적어 검출되지 않았으며, Claudin 1, Claudin 7, Claudin 8, Occludin, JAM A, ZO-1, ZO-2, Tricellulin은 대조군 대비 발현량에 큰 차이를 보이지 않았다. 그러나 Claudin 2, Claudin 3, Claudin 4, Claudin 6, Claudin 9, Claudin 18의 경우 대조군 대비 소목 및 브라질린 처리 시 발현량이 증가되는 것을 확인하였다. FIG. 1 shows the results of measuring the amount of expression of Claudin mRNA, which is a gene related to tight junction of dermal keratinocytes by the extract of jojoba. As shown in FIG. 1, the amount of expression of
Claudin 2는 소목을 처리하였을 경우 2.50배, 브라질린을 처리하였을 경우 3.14배 더 발현량이 증가하였으며, Claudin 3는 소목에 의해 1.86배, 브라질린에 의해 2.03배 더 발현량이 증가한 것을 알 수 있었다. 소목은 Claudin 4의 발현량에 큰 영향을 주지 않았지만, 브라질린은 Claudin 4의 발현량을 1.97배 더 증가시켰다. The expression level of
또한 Claudin 6는 소목 처리 시 3.01배, 브라질린 처리 시 3.46배 발현량이 증가되어 실험을 수행한 15가지 TJ 관련 유전자 중 소목과 브라질린에 의해 발현량이 가장 많이 증가된 것을 확인할 수 있었다. Claudin 9은 소목에 의해 2.64배, 브라질린에 의해 2.08배 발현량이 증가하였으며, Claudin 18은 소목에 의해 1.50배로 미미하게 증가되었으나, 브라질린에 의해 2.87배 증가한 것을 알 수 있었다. In addition, the expression level of
소목과 브라질린을 처리하여 발현량이 올라간 6가지 TJ 관련 유전자 중에 Claudin 9을 제외한 나머지 Claudin 2, 3, 4, 6, 18은 소목에 비해 브라질린에 의해 발현량이 더 증가한 것을 확인할 수 있었다. 이는 브라질린이 소목의 대표 지표 물질이기 때문인 것으로 사료된다. The expression levels of
실시예Example 3: 표피세포 3: epidermal cells 피부저항Skin resistance 측정 Measure
Brazilin 및 소목이 상피세포 간 장벽(epithelial barrier)에 미치는 영향을 확인하기 위하여 트랜스 상피 전기 저항(transepithelial electric resistance, TEER)을 측정하였다. 12 well plate 0.4 ㎛ pore Transparent PET Membrane (Corning, USA)에, HaCaT 5.0 × 104 cell/insert 밀도로 seed하여 TEER 측정값이 100 - 120 ohm·cm2까지 도달하도록 배양한 뒤, 4.37μM의 Brazilin과 2.5㎍/ml의 소목을 처리한 후 0, 24 시간 간격으로 TEER 값을 측정하였다. 이때 TEER 값은 ohm (Ω) × ㎠으로 표시하였다. 본 실시예에서 세포 장벽 강화를 확인하기 위해 EVOM2 (Epithelial Volt Ohm Meter 2, World Precision Instruments, USA)를 이용하여 측정하였다. 양성 대조군으로 resveratrol (50 μM), 음성대조군은 Deoxynivalenol (DON, 4μM)을 사용하여 세포 장벽 강화를 비교 측정하였다Transepithelial electric resistance (TEER) was measured to determine the effect of Brazilin and alum on the epithelial barrier. The seeds were seeded with HaCaT 5.0 × 10 4 cells / insert density in a 12-well plate 0.4 μm pore Transparent PET Membrane (Corning, USA) and cultured to reach a TEER measurement value of 100-120 ohm · cm 2 . And 2.5 μg / ml of starch, respectively, and TEER values were measured at intervals of 0, 24 hours. At this time, the TEER value is expressed as ohm (Ω) × ㎠. In this example, EVOM2 (Epithelial
Brazilin과 소목에 의한 세포장벽 기능 강화에 따른 세포 투과도 감소효과를 관찰하기 위해 TEER 값(Ohm)을 측정하였다. 도 2는 트랜스 상피 전기 저항(TEER) 실험을 통한 세포 장벽 강화 효과 측정 결과이다. 도 2를 참조하면, 정상적인 세포배양 조건인 대조군(Control) 121.0 ± 4.6 대비 음성대조군인 4μM Deoxynivalenol(DON)는 113.0 ± 4.4 Ohm으로 TEER값이 감소한 반면 25μM, 50μM Resveratrol(Res)은 각각 128.0 ± 1.7, 133.0 ± 4.6으로 TEER값이 증가되어 세포장벽 기능이 강화됨을 확인하였다. Brazilin을 4.37μM로 처리한 경우 135.3 ± 4.5의 결과값을 나타내었고, 양성대조군인 resveratrol 50μM과 비슷한 결과값을 나타내었다. 이는 Brazilin (4.37μM)에 의해 세포투과성이 감소함을 의미한다. The TEER value (Ohm) was measured to observe the decrease of cell permeability due to enhancement of cell barrier function by Brazilin and. FIG. 2 shows the measurement results of the cell barrier strengthening effect through the trans-epithelial electrical resistance (TEER) experiment. Referring to FIG. 2, the TEER value was decreased to 113.0 ± 4.4 Ohm for 4 μM Deoxynivalenol (DON), which is a negative control group, compared to the control (control) 121.0 ± 4.6 for normal cell culture condition, while 25 μM and 50 μM Resveratrol (Res) , And 133.0 ± 4.6, indicating that the cell barrier function was enhanced by increasing the TEER value. When Brazilin was treated at 4.37 μM, the results were 135.3 ± 4.5 and resveratrol was similar to 50 μM. This means that the cellular permeability is decreased by Brazilin (4.37 μM).
한편, 상기에서는 본 발명을 특정의 바람직한 실시예에 관련하여 도시하고 설명하였지만, 이하의 특허청구범위에 의해 마련되는 본 발명의 기술적 특징이나 분야를 이탈하지 않는 한도 내에서 본 발명이 다양하게 개조 및 변화될 수 있다는 것은 당업계에서 통상의 지식을 가진 자에게 명백한 것이다.While the present invention has been particularly shown and described with reference to preferred embodiments thereof, it is to be understood that the invention is not limited to the disclosed embodiments, but, on the contrary, It will be apparent to those skilled in the art that changes may be made.
Claims (10)
Claims: 1. A cosmetic composition for enhancing skin barrier function, comprising a root extract as an active ingredient.
상기 소목 추출물은 (a) 물, 탄소수 1-4의 무수 또는 함수 저급 알코올, 아세톤, 에틸 아세테이트, 클로로포름, 부틸아세테이트 및 1,3-부틸렌 글리콜로 구성된 군으로부터 선택되는 추출용매를 이용한 용매 추출법, (b) 초임계 추출법 또는 (c) 초음파 추출법을 이용하여 추출한 것을 특징으로 하는 화장료 조성물.
The method according to claim 1,
(A) a solvent extraction method using an extraction solvent selected from the group consisting of water, an anhydrous or a lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, butyl acetate and 1,3-butylene glycol, (b) supercritical extraction method or (c) ultrasonic extraction method.
상기 화장료 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이로 구성된 군으로부터 선택되는 제형인 것을 특징으로 하는 화장료 조성물.
The method according to claim 1,
The cosmetic composition may be in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray ≪ / RTI >
A health functional food for improving the barrier function of skin containing an extract of johoba as an active ingredient.
상기 소목 추출물은 (a) 물, 탄소수 1-4의 무수 또는 함수 저급 알코올, 아세톤, 에틸 아세테이트, 클로로포름, 부틸아세테이트 및 1,3-부틸렌 글리콜로 구성된 군으로부터 선택되는 추출용매를 이용한 용매 추출법, (b) 초임계 추출법 또는 (c) 초음파 추출법을 이용하여 추출한 것을 특징으로 하는 건강기능식품.
The method according to claim 1,
(A) a solvent extraction method using an extraction solvent selected from the group consisting of water, an anhydrous or a lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, butyl acetate and 1,3-butylene glycol, (b) a supercritical extraction method or (c) an ultrasonic extraction method.
A composition for accelerating the formation of tight junctions comprising an extract of a root extract as an active ingredient.
상기 소목 추출물은 (a) 물, 탄소수 1-4의 무수 또는 함수 저급 알코올, 아세톤, 에틸 아세테이트, 클로로포름, 부틸아세테이트 및 1,3-부틸렌 글리콜로 구성된 군으로부터 선택되는 추출용매를 이용한 용매 추출법, (b) 초임계 추출법 또는 (c) 초음파 추출법을 이용하여 추출한 것을 특징으로 하는 타이트정션 형성 촉진 조성물.
The method according to claim 1,
(A) a solvent extraction method using an extraction solvent selected from the group consisting of water, an anhydrous or a lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, butyl acetate and 1,3-butylene glycol, (b) a supercritical extraction method or (c) an ultrasonic extraction method.
A skin moisturizer containing an aloe extract as an active ingredient.
상기 소목 추출물은 (a) 물, 탄소수 1-4의 무수 또는 함수 저급 알코올, 아세톤, 에틸 아세테이트, 클로로포름, 부틸아세테이트 및 1,3-부틸렌 글리콜로 구성된 군으로부터 선택되는 추출용매를 이용한 용매 추출법, (b) 초임계 추출법 또는 (c) 초음파 추출법을 이용하여 추출한 것을 특징으로 하는 피부보습제.
The method according to claim 1,
(A) a solvent extraction method using an extraction solvent selected from the group consisting of water, an anhydrous or a lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, butyl acetate and 1,3-butylene glycol, (b) supercritical extraction method or (c) ultrasonic extraction method.
A cosmetic method characterized by having the effect of applying the cosmetic composition of claim 1 to human skin to enhance skin barrier function.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170013879A KR101946880B1 (en) | 2017-01-31 | 2017-01-31 | Composition for improving skin barrier function and skin moisturizing agent comprising an extract of Caesalpinia sappn L. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170013879A KR101946880B1 (en) | 2017-01-31 | 2017-01-31 | Composition for improving skin barrier function and skin moisturizing agent comprising an extract of Caesalpinia sappn L. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180089151A true KR20180089151A (en) | 2018-08-08 |
| KR101946880B1 KR101946880B1 (en) | 2019-02-12 |
Family
ID=63229954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170013879A KR101946880B1 (en) | 2017-01-31 | 2017-01-31 | Composition for improving skin barrier function and skin moisturizing agent comprising an extract of Caesalpinia sappn L. |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101946880B1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020071630A1 (en) * | 2018-10-02 | 2020-04-09 | 주식회사 엘지생활건강 | Composition for improving skin comprising extracts of natural products |
| KR102271354B1 (en) * | 2020-01-16 | 2021-06-30 | 주식회사 익스플즌 | Cleansing cosmetic composition containing high content of oil |
| KR20210092440A (en) * | 2020-01-16 | 2021-07-26 | 주식회사 익스플즌 | Mascara cleansing cosmetic composition |
| KR20220107803A (en) | 2021-01-26 | 2022-08-02 | 한국한의약진흥원 | Cosmetic composition for skin improvement with antioxidizing, whitening and antiwrinkle effect comprising 3-Deoxysappanone B |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0393710A (en) * | 1989-09-07 | 1991-04-18 | Ichimaru Pharcos Co Ltd | External preparation or cosmetic for skin or hair containing rearing inhibitor of propionibacterium acnes |
| KR100750657B1 (en) | 2005-12-09 | 2007-08-20 | 한국과학기술연구원 | Use of the extract of Caesalpinia sappan L. and compounds therefrom |
-
2017
- 2017-01-31 KR KR1020170013879A patent/KR101946880B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0393710A (en) * | 1989-09-07 | 1991-04-18 | Ichimaru Pharcos Co Ltd | External preparation or cosmetic for skin or hair containing rearing inhibitor of propionibacterium acnes |
| KR100750657B1 (en) | 2005-12-09 | 2007-08-20 | 한국과학기술연구원 | Use of the extract of Caesalpinia sappan L. and compounds therefrom |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020071630A1 (en) * | 2018-10-02 | 2020-04-09 | 주식회사 엘지생활건강 | Composition for improving skin comprising extracts of natural products |
| KR102271354B1 (en) * | 2020-01-16 | 2021-06-30 | 주식회사 익스플즌 | Cleansing cosmetic composition containing high content of oil |
| KR20210092440A (en) * | 2020-01-16 | 2021-07-26 | 주식회사 익스플즌 | Mascara cleansing cosmetic composition |
| KR20220107803A (en) | 2021-01-26 | 2022-08-02 | 한국한의약진흥원 | Cosmetic composition for skin improvement with antioxidizing, whitening and antiwrinkle effect comprising 3-Deoxysappanone B |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101946880B1 (en) | 2019-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101946880B1 (en) | Composition for improving skin barrier function and skin moisturizing agent comprising an extract of Caesalpinia sappn L. | |
| CN109152724B (en) | Synergistic extract of palmaria palmiformis and jasmine, composition containing synergistic extract and application of synergistic extract | |
| KR20110074857A (en) | Compositions for treating or alleviating skin diseases or disorders related to an enhanced level of anti-microbial peptides and proteins | |
| EP2200574B1 (en) | Novel use of panduratin derivatives or extract of kaempferia pandurata comprising the same | |
| KR101124971B1 (en) | Cosmetic composition containing Salicornia herbacea callus Extracts and Laminaria digitata Extracts for Improving Skin Wrinkle or enhancing skin Elasticity | |
| CN106132387B (en) | Cosmetic composition for skin moisture containing mineral component and quinoa extract | |
| KR100762287B1 (en) | Cosmetic composition with high amount of minerals comprising deep sea water and extract of peach blossom | |
| KR101489935B1 (en) | Method for preparing mugwort extract and cosmetic composition comprising mugwort extract prepared therefrom | |
| KR102298335B1 (en) | Cosmetic composition for skin barrier comprising extract of Buddleia officinalis or fractions thereof | |
| KR20210091430A (en) | Cosmetic composition containing natural complex extracts as active ingredient | |
| JP6173362B2 (en) | Skin barrier function improving agent, intercellular adhesion structure formation promoter, tight junction formation promoter, TRPV4 activator, intracellular Ca concentration increase promoter and sebum production promoter | |
| KR101805015B1 (en) | Skin external composition containing Citron Extract, Ulmus Davidiana root Extract, and Salicornia herbacea Extract | |
| KR20200057126A (en) | Composition for Regenerating Skin and Enhancing Hair Growth Comprising Apigenin | |
| JP5937782B2 (en) | V-type collagen gene transcription promoter | |
| KR20100055734A (en) | Skin external composition for enhancing skin barrier or moisturizing skin containing 7,3',4'-trihydroxyisoflavone | |
| JP5171752B2 (en) | Topical skin preparation | |
| KR101892641B1 (en) | Skin External Composition Containing Ulmus Davidiana Extract, Dioscorea Japonica Extract or Morus Alba Leaf Extract | |
| JP2022022590A (en) | Composition for application to skin to increase expression of ccn1 and ccn2 | |
| KR100780078B1 (en) | Composition with high amount of minerals for human body cleansing comprising nutrient salts of deep sea water and extract of peach blossom | |
| KR101522369B1 (en) | Cosmetic composition containing Ailanthi Radicis Cortex extract and Galium verum extract for anti-aging and whitening | |
| TWI740096B (en) | Use of tussilago farfara extract for enhancing the gene expression of tgm, krt, aqp, flg, gba, and has | |
| KR20180009367A (en) | Composition containing natural extracts | |
| JP7122169B2 (en) | Melanin degradation accelerator and whitening cosmetic | |
| JP6417113B2 (en) | Involucrin expression inhibitor | |
| KR20170029449A (en) | Oligonucleotides down-regulating the expression of TSLP and the composites for cosmetic or pharmaceutical |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |